Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
MINNEAPOLIS, November 18, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer’s disease. The collaboration leverages Bio-Techne’s Ella™ fully automated, multiplexing immunoassay platform and ALZpath’s proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. […]
ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
CARLSBAD, Calif., Oct. 30, 2024 /PRNewswire/ — ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced that it has been honored in TIME’s annual Best Inventions list, which features 200 extraordinary innovations changing our lives. The ALZpath proprietary pTau 217 antibody was recognized in the medical […]
New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
Study Showed High Accuracy in Determining Amyloid Burden Across All Stages of Alzheimer’s Disease Progression, Supporting Early Detection, Treatment, Interventions and Tracking ALZpath pTau217 Antibody Has Now Been Utilized in Over 40 Cohort Studies with 50,000 Samples CARLSBAD, California, July 29, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for […]
ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
Beckman Coulter to Utilize the ALZpath pTau217 Antibody to Detect Key Biomarker for Alzheimer’s Disease on its DxI 9000 Immunoassay Analyzer July 15, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced today that it has signed a licensing agreement with Beckman Coulter Diagnostics, […]
ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
Company Co-founder Venkat Shastri to Remain Active in Advisory Role CARLSBAD, CA, July 9, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company […]
ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease
Agreement Paves the Way for New Era of Accessible, Precise, and Reliable Diagnostic Blood Tests Capable of Identifying Alzheimer’s Disease in its Earliest Stages CARLSBAD, California, June 10th, 2024 — ALZpath, Inc. (ALZpath), a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced a strategic license agreement with Roche […]
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
CARLSBAD, Calif., — February 29th, 2024 — ALZpath, Inc. (ALZpath), Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreement with ALZpath, a leading developer of diagnostic solutions in Alzheimer’s disease and related dementias. This collaboration marks a significant milestone in the advancement […]
New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain
ALZpath’s Blood-Based Test Delivers Accuracy Comparable to More Invasive and Expensive CSF-Based Tests, Reducing the Need for Confirmatory Testing By ~80% CARLSBAD, Calif., — January 22, 2024 — ALZpath, Inc. (ALZpath), a leader in Alzheimer’s diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau […]
ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay
Funding will accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer’s disease. Carlsbad, CA – July 18, 2023 – ALZpath, a leading developer of innovative diagnostic solutions for Alzheimer’s disease, is proud to announce that they have received funding from […]
ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
Carlsbad, Calif., Nov. 28, 2022 – ALZpath, Inc. announced today the launch of its first diagnostic assay for detection of phosphorylated tau 217 (pTau217) in blood. pTau217 is widely considered to be one of the leading transformative Alzheimer’s disease (AD) diagnostic biomarkers by enabling earlier and more accurate AD diagnoses, better stratifying patients for clinical […]